News
MEDP
446.05
-15.90%
-84.30
Medpace Holdings’ Earnings Call Signals Growth Amid Volatility
TipRanks · 7h ago
Baird upgrades Medpace to Outperform on earnings selloff
TipRanks · 10h ago
Noteworthy Tuesday Option Activity: MEDP, THC, AZO
NASDAQ · 11h ago
Medpace upgraded to Outperform from Neutral at Baird
TipRanks · 12h ago
Dow Jones Reaches Record Highs, Software Stocks Extend Rebound: What's Moving Markets Tuesday?
Benzinga · 13h ago
Medpace falls -14.7%
TipRanks · 14h ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 14h ago
Medpace outlines 2026 revenue growth of up to 12.8% amid backlog normalization and metabolic trial shifts
Seeking Alpha · 14h ago
Medpace slumps after Q4 earnings on book-to-bill ratio
Seeking Alpha · 15h ago
Medpace Holdings Down Over 15%, On Pace for Largest Percent Decrease Since July 2024 -- Data Talk
Dow Jones · 15h ago
Medpace (MEDP) Q4 2025 Earnings Call Transcript
The Motley Fool · 16h ago
CRO peers lower after Medpace earnings, comments on cancellations
TipRanks · 16h ago
Here are the major earnings after the close Monday
Seeking Alpha · 16h ago
Medpace says cancellations ‘widespread’ in Q4
TipRanks · 17h ago
MEDP Q4 Deep Dive: Cancellations and Metabolic Trial Mix Pressure Margins Despite Strong Growth
Barchart · 18h ago
Analysts Offer Insights on Healthcare Companies: Medpace Holdings (MEDP), Wave Life Sciences (WVE) and Collegium Pharmaceutical (COLL)
TipRanks · 19h ago
Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT) and Medpace Holdings (MEDP)
TipRanks · 21h ago
Analysts Offer Insights on Healthcare Companies: Medpace Holdings (MEDP) and Molina Healthcare (MOH)
TipRanks · 23h ago
Medpace Holdings: Great Quarter, Stale Backlog, Full Valuation
Seeking Alpha · 1d ago
Medpace Holdings, Inc. Q4 Income Advances, Beats Estimates
NASDAQ · 1d ago
More
Webull provides a variety of real-time MEDP stock news. You can receive the latest news about Medpace Holdings through multiple platforms. This information may help you make smarter investment decisions.
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.